Publications
70
Citations
728
Est. group size
~17
Recurring co-author estimate
Active years
26
Publishing since 2001
Shivani Handa's research focuses on blood cancers, especially acute myeloid leukemia (AML), myeloproliferative neoplasms (a group of blood disorders including myelofibrosis and essential thrombocythemia), and chronic myeloid leukemia. Much of the work involves clinical trials and large multicenter or retrospective studies evaluating drug combinations (such as venetoclax, azacitidine, ruxolitinib, and menin inhibitors), risk-prediction models, and treatment-related complications like infections after CAR-T cell therapy. This work is aimed at improving prognosis assessment and treatment strategies for older or higher-risk blood cancer patients.
Publication output has grown substantially in recent years, rising from a handful of papers per year earlier in the decade to 24 in 2025, indicating an accelerating and currently active research output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Clinical outcomes of older patients with <i>NPM1</i> -mutated or <i>KMT2A-</i> rearranged AML before menin inhibitors: a Beat AML report
Blood Advances · 2026
- Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Haematologica · 2026
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Journal of Clinical Oncology · 2026
- Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression
Blood · 2025
- Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomes
The Oncologist · 2025
- <i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
Haematologica · 2025
- Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial
Cancers · 2025
- Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study
Blood · 2025
- Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium
Blood · 2025
- CT-1192: Characterization of Infectious Complications Following CAR T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: MPN-874 CPX-351 in Combination With Ruxolitinib for the Treatment of Myeloproliferative Neoplasm-Accelerated/Blast Phase
Clinical Lymphoma Myeloma & Leukemia · 2025
- MPN-1218: Ruxolitinib and Interferon Alfa Induce Superior Rates of Complete Peripheral Blood Count Remission Compared With Anagrelide in Hydroxyurea-Exposed Essential Thrombocythemia
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: CT-1192 Characterization of Infectious Complications Following Car T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome
Clinical Lymphoma Myeloma & Leukemia · 2025
- MPN-874: CPX-351 in Combination With Ruxolitinib for the Treatment of Myeloproliferative Neoplasm-Accelerated/Blast Phase
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: AML-442 RAS Mutations Negate the Favorable Impact of NPM1 in Older Patients With Newly-Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
Clinical Lymphoma Myeloma & Leukemia · 2025
- Blood×20
- Clinical Lymphoma Myeloma & Leukemia×11
- Journal of Clinical Oncology×8
- Blood Advances×2
- Journal of Scientific Innovation in Medicine×2
- Deedra Nicolet
Medicine · The Ohio State University
- Ann‐Kathrin Eisfeld
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Alice S. Mims
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile